date:Aug 07, 2014
ays and biologically active small molecule compounds which are sold to biomedical researchers and clinical research laboratories. ProteinSimple customers include top pharmaceutical and biotechnology companies. ProteinSimple instrument placements have the potential to drive additional antibody sales from both Bio-Techne and Novus Biologicals, Bio-Technes most recent acquisition. Bio-Technes CEO Charles R. Kummeth and ProteinSimple CEO Tim Harkness are both excited by the excellent fit of the two